Page 461 - Essential Haematology

Index / 447

nucleophosmin (NPM) gene paraprotein(s) 273 phosphorus-32, polycythaemia vera
mutations 157, 180 multiple myeloma 276 207
nutritional support, haematological venous thrombosis 369 phototherapy, haemolytic disease of
malignancies 169 paraproteinaemia 131, 273 the newborn 422
features of benign/malignant pica 40
O 282 PIVKA (proteins formed in vitamin
O blood group 367 paroxysmal cold haemoglobinuria K absence) 354
gene 399 84, 86–7 plant derivatives, haematological
oestrogen therapy, venous venous thrombosis 369 malignancies 174, 176
thrombosis risk 369 paroxysmal nocturnal plasma 408, 409
oncogenes, haemopoietic haemoglobinuria (PNH) viscosity 394, 395
malignancies 154–5 75 volume 425
opsonization 114 parvovirus B19, red cell aplasia plasma cell(s)
oral anticoagulants, venous 295 HIV infection 391
thrombosis 374–6, 377 Paterson–Kelly syndrome 39, 41 immunophenotype in multiple
oral contraceptives, oestrogen levels Pearson’s syndrome 47 myeloma 277
369 Pelger–Huët anomaly 116 plasma cell leukaemia 282
oropharyngeal lymphoid structures, myelodysplasia 217, 218 plasma cell neoplasms 273
non-Hodgkin lymphoma pentose phosphate pathway see plasma exchange, thrombotic
257 hexose monophosphate thrombocytopenic
Oroya fever 389 pathway purpura 338
osmotic fragility, hereditary periarteriolar lymphatic sheath plasmacytoma, solitary 281–2
spherocytosis 78 (PALS) 143 plasmapheresis
osteomyelitis, Salmonella 102, peripheral blood stem cells, hyperviscosity syndrome 286
103 collection 230, 298, 299 acute 265
osteoporosis pernicious anaemia 63, 64 plasmin 326, 327
haematological changes 391–2 antibodies 64 inactivation 327
heparin-induced 374 associations 64 plasminogen 326
thalassaemia major 96 autoimmune 64 Plasmodium falciparum 391, 393
oxygen autoimmune thyroid disease 388 platelet(s) 315–16, 317, 318–19,
exchange 21 vitamin B 12 therapy 70 320, 321
transport 19, 21 phagocytes 109–10 abnormalities
attraction to bacteria/ in malignancy 382–3, 384,
P infl ammation site 114 385
P antibodies 402 digestion 114–15 in renal failure 387
p53 tumour-suppressor gene 11, function 110 activation 325
12 defects 115–16 adhesion 318, 319
mutations 157 killing 114–15 aggregation 318, 319, 324–5
packed cell volume (PCV) abnormalities 116 amplifi cation 318, 320
anaemia 25 phagocytosis 114, 115 antigens 318
normal values 425 defects 116 deposition in atherosclerosis 363
pain management, haematological phagosomes 115 diseases 331
malignancies 169 pharyngeal webs 39, 41 essential thrombocythaemia 209
pancytopenia 289 Philadelphia chromosome function 318–19, 320, 321
hairy cell leukaemia 241–2 ALL 228, 232 tests 328, 343
myelodysplasia 217, 218 CML 192, 193, 194 function inhibitors 320
Pappenheimer bodies (siderotic phosphatidylinositol 3 (PI3) kinase glycoproteins 316, 318
granules) 30 8, 9, 10 haemostatic response 324–5